Orgenesis Inc (ORGS) - Total Liabilities

Latest as of September 2024: $53.62 Million USD

Based on the latest financial reports, Orgenesis Inc (ORGS) has total liabilities worth $53.62 Million USD as of September 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Orgenesis Inc generate cash to assess how effectively this company generates cash.

Orgenesis Inc - Total Liabilities Trend (2008–2023)

This chart illustrates how Orgenesis Inc's total liabilities have evolved over time, based on quarterly financial data. Check ORGS cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.

Orgenesis Inc Competitors by Total Liabilities

The table below lists competitors of Orgenesis Inc ranked by their total liabilities.

Company Country Total Liabilities
Academies Australasia Group Ltd
AU:AKG
Australia AU$57.58 Million
bioAffinity Technologies, Inc.
NASDAQ:BIAF
USA $3.68 Million
Fanhua Inc
F:4CIA
Germany €1.52 Billion
Saxlund Group AB
ST:SAXG
Sweden Skr75.97 Million
Vigor Kobo Co Ltd
TWO:2733
Taiwan NT$144.76 Million
Total Transport Systems Limited
NSE:TOTAL
India Rs939.08 Million
Prg Holdings Bhd
KLSE:7168
Malaysia RM229.13 Million
Cenntro Electric Group Ltd
NASDAQ:CENN
USA $36.57 Million

Liability Composition Analysis (2008–2023)

This chart breaks down Orgenesis Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Orgenesis Inc (ORGS) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 0.07 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -2.24 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.81 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Orgenesis Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Orgenesis Inc (2008–2023)

The table below shows the annual total liabilities of Orgenesis Inc from 2008 to 2023.

Year Total Liabilities Change
2023-12-31 $35.53 Million +12.26%
2022-12-31 $31.65 Million +49.24%
2021-12-31 $21.21 Million -15.01%
2020-12-31 $24.96 Million -71.12%
2019-12-31 $86.42 Million +84.66%
2018-12-31 $46.80 Million 0.00%
2018-11-30 $46.80 Million +81.75%
2017-12-31 $25.75 Million +12.40%
2016-12-31 $22.91 Million -49.30%
2015-12-31 $45.19 Million +764.30%
2014-12-31 $5.23 Million +143.33%
2013-12-31 $2.15 Million +553.63%
2012-12-31 $328.72K +286.67%
2011-12-31 $85.01K +612.12%
2010-12-31 $11.94K +98.97%
2009-12-31 $6.00K +71.43%
2008-12-31 $3.50K --

About Orgenesis Inc

NASDAQ:ORGS USA Biotechnology
Market Cap
$10.08 Million
Market Cap Rank
#26923 Global
#5349 in USA
Share Price
$1.95
Change (1 day)
+0.08%
52-Week Range
$1.90 - $2.09
All Time High
$2.09
About

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of res… Read more